Publications (45) Zinnia Patricia Parra Guillén publications

filter_list

2025

  1. Development and Application of Physiologically-Based Pharmacokinetic Model to Predict Systemic and Organ Exposure of Colorectal Cancer Drugs

    Pharmaceutics, Vol. 17, Núm. 1

2024

  1. Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab

    Clinical Pharmacology and Therapeutics, Vol. 116, Núm. 5, pp. 1304-1313

  2. Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies

    Frontiers in Immunology, Vol. 15

  3. Pharmacodynamic Model of the Hemodynamic Effects of Propofol and Remifentanil and Their Interaction with Noxious Stimulation †

    Pharmaceutics, Vol. 16, Núm. 12

2023

  1. A physiologically based pharmacokinetic model for V937 oncolytic virus in mice

    Frontiers in Pharmacology, Vol. 14

  2. Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling

    Clinical Pharmacology and Therapeutics, Vol. 114, Núm. 3, pp. 623-632

  3. Characterization of the interplay between different biological factors driving tumor growth dynamics in the absence of treatment.

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  4. Editorial: Innovative pharmacometric approaches to inform drug development and clinical use

    Frontiers in Pharmacology

  5. Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment

    PLoS Computational Biology, Vol. 19, Núm. 10

  6. Population pharmacokinetics of sublingually administered tacrolimus in infants and young children with liver transplantation

    British Journal of Clinical Pharmacology, Vol. 89, Núm. 3, pp. 1115-1126

2022

  1. Mechanistic modelling of enzyme-restoration effects of new recombinant liver-targeted proteins in acute intermittent porphyria

    British Journal of Pharmacology, Vol. 179, Núm. 14, pp. 3815-3830

  2. Relevance of primary lesion location, tumour heterogeneity and genetic mutation demonstrated through tumour growth inhibition and overall survival modelling in metastatic colorectal cancer

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 1, pp. 166-177

  3. Use of PK/PD modeling to minimize the environmental impact of the use of doramectin 3.5% against Rhipicephalus Microplus in cattle

    Revista Colombiana de Ciencias Químico-Farmacéuticas, Vol. 51, Núm. 3, pp. 1536-1537

2021

  1. A quantitative systems pharmacology model for acute viral hepatitis B

    Computational and Structural Biotechnology Journal, Vol. 19, pp. 4997-5007

  2. Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration

    Frontiers in Pharmacology, Vol. 12

  3. Semi-mechanistic model for the antitumor response of a combination cocktail of immuno-modulators in non-inflamed (Cold) tumors

    Cancers, Vol. 13, Núm. 20

2020

  1. A quantitative systems pharmacology model for the key interleukins involved in Crohn’s disease

    Journal of Pharmacology and Experimental Therapeutics, Vol. 372, Núm. 3, pp. 299-307

  2. Disease pharmacokinetic–pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies

    British Journal of Pharmacology, Vol. 177, Núm. 14, pp. 3168-3182

  3. Machine Learning Analysis of Individual Tumor Lesions in Four Metastatic Colorectal Cancer Clinical Studies: Linking Tumor Heterogeneity to Overall Survival

    AAPS Journal, Vol. 22, Núm. 3

  4. Model-Informed Dose Selection for Xentuzumab, a Dual Insulin-Like Growth Factor-I/II—Neutralizing Antibody

    Clinical Pharmacology and Therapeutics, Vol. 107, Núm. 3, pp. 597-606